Progress on common EU patent with agreement on site of Unified Patent Court

2 July 2012

The European Council has finally reached agreement on the location of a Unified Patent Court (UPC) for the European Union, Commissioner for Internal Markets and Services Michael Barnier announced on Friday, saying this was a decisive step towards the creation of a unitary patent and a common patent court in Europe. Efforts to create a common patent applicable across all European countries have been made since the 1960s but for a number of reasons have never been successful.

After the political agreement reached at the Competitiveness Council in December 2011, the negotiations on the entire package had been stalled due to a disagreement on the location of the seat of the central division of the UPC. Friday’s compromise agreement places the seat of the UPC's Central Division in Paris, France. Specialized clusters of the UPC’s central division will also be set up - one in London, UK, the other in Munich, Germany.

“The reform will create a simpler application process and considerably reduce the costs for obtaining patent protection. All future unitary patents will eventually be available in all official EU languages, thus ensuring the dissemination of knowledge and benefiting inventors. I hope that Spain and Italy will also join the new regime soon, the Commissioner stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology